Rhematoid Arthritis - Reducing the signs and symptoms and slowing the progression of structural damage in moderate to severe active Rheumatoid Arthritis.
Must be 18 years or older.
Must be prescribed by or in consultation with a rheumatologist.
For initiation of treatment, a prior authorization form and relevant chart notes documenting medical rationale are required and for continuation of therapy, documentation of successful response to the medication may be necessary.
Anakinra will be approved for RA when all of the following conditions are met:
Reauthorization will require documentation of adequate response to treatment.
Use in combination with a TNF agent.
Initial authorization will be for up to six months. Reauthorization will be for up to one year.